HSA has recalled 3 of the affected Metformin products from 4 December 2019. It has found NDMA (N-Nitrosodimethylamine), a nitrosamine impurity, in 3 of the 46 metformin products sold in Singapore. The 3 affected Metformin products, are all single-ingredient prolonged release metformin products, namely Glucient XR Metformin HCI 500mg Extended-release, Mijumet 1000mg Prolonged Release Tablets, Meijumet 750mg Prolonged Release Tablets.
It is estimated that about 5,000 patients (about 2,500 patients each in the private and public healthcare sector) are affected.
A series of recall approach of the affected Metformin is advised in the link attached *here*
Relevant information is also available on the HSA website at www.hsa.gov.sg